system
clinician
adopt
univers
consolid
framework
recogn
stage
progress
ill
order
deploy
investig
target
therapi
like
save
live
largest
report
chines
center
diseas
control
prevent
summar
find
case
note
mild
natur
overal
case
fatal
rate
small
subgroup
present
respiratori
failur
septic
shock
multiorgan
dysfunct
result
fatal
half
case
find
suggest
within
group
opportun
life
save
measur
may
pertin
diseas
manifest
support
measur
initi
quarantin
howev
systemat
diseas
modifi
therapeut
approach
remain
empir
pharmacotherapi
target
viru
hold
greatest
promis
appli
earli
cours
ill
use
advanc
stage
may
doubt
similarli
use
antiinflammatori
therapi
appli
earli
may
necessari
could
even
provok
viral
replic
case
corticosteroid
appear
two
distinct
overlap
patholog
subset
first
trigger
viru
second
host
respons
whether
nativ
state
immunoquiesc
state
elderli
immunosuppress
state
heart
transplant
diseas
tend
present
follow
two
phase
albeit
differ
level
sever
earli
report
heart
transplant
suggest
symptom
express
phase
establish
infect
similar
nonimmunosuppress
individu
howev
limit
seri
second
wave
determin
hostinflammatori
respons
appear
milder
possibl
due
concomit
use
immunomodulatori
drug
similarli
epidemiolog
studi
wuhan
cohort
patient
suggest
precautionari
measur
social
distanc
sanit
gener
hygien
allow
heart
transplant
recipi
experi
low
rate
ill
cours
know
asymptomat
carrier
sinc
surveybas
studi
univers
test
earli
month
employ
one
interest
fact
studi
mani
heart
transplant
recipi
hematolog
chang
lymphopenia
due
effect
immunosuppress
therapi
may
obfusc
laboratori
interpret
infect
patient
get
infect
much
confus
abound
therapeut
tactic
employ
imper
structur
approach
clinic
phenotyp
undertaken
distinguish
phase
viral
pathogen
domin
versu
host
inflammatori
respons
overtak
patholog
editori
propos
clinic
stage
system
establish
standard
nomenclatur
uniform
evalu
report
diseas
facilit
therapeut
applic
evalu
respons
propos
use
classif
system
recogn
ill
exhibit
three
grade
increas
sever
correspond
distinct
clinic
find
respons
therapi
clinic
outcom
figur
initi
stage
occur
time
inocul
earli
establish
diseas
peopl
involv
incub
period
associ
mild
often
nonspecif
symptom
malais
fever
dri
cough
period
multipli
establish
resid
host
primarili
focus
respiratori
system
similar
older
rel
sarscov
respons
sar
outbreak
bind
target
use
angiotensinconvert
enzym
receptor
human
cell
receptor
abundantli
present
human
lung
small
intestin
epithelium
well
vascular
endothelium
result
airborn
method
transmiss
well
affin
pulmonari
receptor
infect
usual
present
mild
respiratori
system
symptom
diagnosi
stage
includ
respiratori
sampl
pcr
serum
test
igg
igm
along
chest
imag
complet
blood
count
cbc
liver
function
test
cbc
may
reveal
lymphopenia
neutrophilia
without
signific
abnorm
treatment
stage
primarili
target
toward
symptomat
relief
viabl
antivir
therapi
remdesivir
proven
benefici
target
select
patient
stage
may
reduc
durat
symptom
minim
contagi
prevent
progress
sever
patient
keep
viru
limit
stage
prognosi
recoveri
excel
stage
ii
moder
pulmonari
involv
iia
without
iib
hypoxia
second
stage
establish
pulmonari
diseas
viral
multipl
local
inflamm
lung
norm
stage
patient
develop
viral
pneumonia
cough
fever
possibl
hypoxia
defin
pao
fio
mmhg
imag
chest
roentgenogram
computer
tomographi
reveal
bilater
infiltr
ground
glass
opac
blood
test
reveal
increas
lymphopenia
along
transamin
marker
system
inflamm
may
elev
remark
stage
patient
would
need
hospit
close
observ
manag
treatment
would
primarili
consist
support
measur
avail
antivir
therapi
remdesivir
avail
compassion
trial
use
note
serum
procalcitonin
low
normal
case
pneumonia
earli
stage
ii
without
signific
hypoxia
use
corticosteroid
patient
may
avoid
howev
hypoxia
ensu
like
patient
progress
requir
mechan
ventil
situat
believ
use
antiinflammatori
therapi
corticosteroid
may
use
judici
employ
thu
stage
ii
diseas
subdivid
stage
iia
without
hypoxia
stage
iib
hypoxia
minor
patient
transit
third
sever
stage
ill
manifest
extrapulmonari
system
hyperinflamm
syndrom
stage
marker
system
inflamm
appear
elev
infect
result
decreas
helper
suppressor
regulatori
cell
count
studi
shown
inflammatori
cytokin
biomark
interleukin
il
granulocytecoloni
stimul
factor
macrophag
inflammatori
protein
tumor
necrosi
creactiv
protein
ferritin
ddimer
significantli
elev
patient
sever
diseas
troponin
ntermin
pro
btype
natriuret
peptid
ntprobnp
also
elev
form
akin
hemophagocyt
lymphohistiocytosi
shlh
may
occur
patient
advanc
stage
diseas
stage
shock
vasoplegia
respiratori
failur
even
cardiopulmonari
collaps
discern
system
organ
involv
even
myocard
would
manifest
stage
tailor
therapi
stage
iii
hing
use
immunomodulatori
agent
reduc
system
inflamm
overwhelmingli
result
multiorgan
dysfunct
phase
use
corticosteroid
may
justifi
concert
use
cytokin
inhibitor
tocilizumab
inhibitor
anakinra
receptor
antagonist
intraven
immun
globulin
ivig
may
also
play
role
modul
immun
system
hyperinflammatori
state
overal
prognosi
recoveri
critic
stage
ill
poor
rapid
recognit
deploy
therapi
may
greatest
yield
first
openlabel
random
control
clinic
trial
antivir
therapi
recent
report
studi
patient
randomli
alloc
antivir
agent
lopinavirritonavir
standard
care
regimen
found
particularli
effect
one
reason
may
patient
enrol
pulmonari
stage
hypoxia
stage
iib
viral
pathogen
may
one
lesser
domin
aspect
overal
pathophysiolog
host
inflammatori
respons
predomin
pathophysiolog
believ
propos
classif
system
ill
serv
develop
uniform
scaffold
build
structur
therapeut
experi
healthcar
system
global
besieg
crisi
patient
without
transplant
disclosur
dr
siddiqi
noth
declar
dr
mehra
report
direct
conflict
pertin
develop
paper
gener
conflict
includ
consult
relationship
abbott
medtron
janssen
mesoblast
portola
bayer
nupulsecv
fineheart
leviticu
tripl
gene
